Investor Library

StemRIMIR LibraryTimely Disclosure Information
April 9, 2025 Timely Disclosure Information StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders Convening and Holding of Extraordinary General Meeting of Shareholders, and Reduction of Capital Stock (Capital Decrease) 
April 3, 2025 Timely Disclosure Information StemRIM Announces Patent Registration (China) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication of Traumatic articular Cartilage Deficiency Syndrome, Osteoarthritis, and Osteochondritis dissecans 
April 2, 2025 Timely Disclosure Information StemRIM Announces the Interim Analysis Results for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke 
March 3, 2025 Timely Disclosure Information StemRIM Announces the Protocol Amendment for the Global Phase 2b Clinical Trial in Patients with Acute Ischemic Stroke 
January 15, 2025 Timely Disclosure Information StemRIM Announces the Extension of the Term for the Tripartite Joint Research Agreement Aimed at Elucidating Skin Anti-Aging Mechanisms 
December 23, 2024 Timely Disclosure Information StemRIM Announces the First Administration of Phase 2 Clinical Trial for Redasemtide Targeting Ischemic Cardiomyopathy 
December 12, 2024 Timely Disclosure Information [Delayed]StemRIM Announces Selection for the AMED Project “FY2024 Project for Fundamental Technology Development toward Industrialization of Regenerative Medicine and Gene Therapy” 
December 11, 2024 Timely Disclosure Information StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation 
December 9, 2024 Timely Disclosure Information StemRIM Announces Patent Registration (Europe) for the Use of the HMGB1 Fragment Peptide Redasemtide as an Additional Therapeutic Indication for Cardiomyopathy and Chronic Heart Failure Caused Thereby 
December 5, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Australia for Peptides Related to the HMGB1 Fragment Peptide Redasemtide 
November 13, 2024 Timely Disclosure Information StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock 
November 5, 2024 Timely Disclosure Information StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide Redasemtide 
October 31, 2024 Timely Disclosure Information Presentation Material for Business Plan and Growth Potential 
September 25, 2024 Timely Disclosure Information StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Company’s Executive Officers Employees and External Collaborators 
September 25, 2024 Timely Disclosure Information Notice Regarding Appointment of Director Candidates